These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease. Gibson CJ; Logue M; Growdon JH Arch Neurol; 1985 May; 42(5):489-92. PubMed ID: 2581531 [TBL] [Abstract][Full Text] [Related]
8. Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease. Blennow K; Wallin A; Gottfries CG; Lekman A; Karlsson I; Skoog I; Svennerholm L Neurobiol Aging; 1992; 13(1):107-13. PubMed ID: 1371850 [TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical responses to therapy in Alzheimer's disease and multi-infarct dementia. Corona GL; Cucchi ML; Frattini P; Santagostino G; Schinelli S; Romani A; Pola A; Zerbi F; Savoldi F Eur Arch Psychiatry Neurol Sci; 1989; 239(2):79-86. PubMed ID: 2478368 [TBL] [Abstract][Full Text] [Related]
10. CSF monoamine metabolites in old age dementias. Parnetti L; Gaiti A; Reboldi GP; Santucci C; Mecocci P; Brunetti M; Cadini D; Senin U Mol Chem Neuropathol; 1992; 16(1-2):143-57. PubMed ID: 1381590 [TBL] [Abstract][Full Text] [Related]
11. Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers. De Bellis MD; Geracioti TD; Altemus M; Kling MA Biol Psychiatry; 1993 Apr 15-May 1; 33(8-9):636-41. PubMed ID: 7687151 [TBL] [Abstract][Full Text] [Related]
12. Decreased monoamine metabolites in frontotemporal dementia and Alzheimer's disease. Sjögren M; Minthon L; Passant U; Blennow K; Wallin A Neurobiol Aging; 1998; 19(5):379-84. PubMed ID: 9880039 [TBL] [Abstract][Full Text] [Related]
13. Higher cerebrospinal fluid MHPG in subjects with dementia of the Alzheimer type. Relationship with cognitive dysfunction. Sheline YI; Miller K; Bardgett ME; Csernansky JG Am J Geriatr Psychiatry; 1998; 6(2):155-61. PubMed ID: 9581211 [TBL] [Abstract][Full Text] [Related]
14. CSF corticotropin-releasing factor (CRF) in Alzheimer's disease: its relationship to severity of dementia and monoamine metabolites. Pomara N; Singh RR; Deptula D; LeWitt PA; Bissette G; Stanley M; Nemeroff CB Biol Psychiatry; 1989 Sep; 26(5):500-4. PubMed ID: 2477071 [TBL] [Abstract][Full Text] [Related]
15. Monoamine metabolites in CSF and suicidal behavior. Träskman L; Asberg M; Bertilsson L; Sjöstrand L Arch Gen Psychiatry; 1981 Jun; 38(6):631-6. PubMed ID: 6166274 [TBL] [Abstract][Full Text] [Related]
16. Analysis of monoamines in the cerebrospinal fluid of Chinese patients with Alzheimer's disease. Liu HC; Yang JC; Chang YF; Liu TY; Chi CW Ann N Y Acad Sci; 1991; 640():215-8. PubMed ID: 1723257 [TBL] [Abstract][Full Text] [Related]
17. The relationship of cerebrospinal fluid monoamine metabolites with clinical response to tetrahydroaminoacridine in patients with Alzheimer's disease. Alhainen K; Helkala EL; Reinikainen K; Riekkinen P J Neural Transm Park Dis Dement Sect; 1993; 5(3):185-92. PubMed ID: 7690228 [TBL] [Abstract][Full Text] [Related]
18. The dexamethasone suppression test in Alzheimer's disease and major depression: relationship to dementia severity, depression, and CSF monoamines. Molchan SE; Hill JL; Mellow AM; Lawlor BA; Martinez R; Sunderland T Int Psychogeriatr; 1990; 2(2):99-122. PubMed ID: 1713799 [TBL] [Abstract][Full Text] [Related]
19. Lower CSF homovanillic acid levels in depressed patients with a history of alcoholism. Sher L; Oquendo MA; Li S; Huang YY; Grunebaum MF; Burke AK; Malone KM; Mann JJ Neuropsychopharmacology; 2003 Sep; 28(9):1712-9. PubMed ID: 12825091 [TBL] [Abstract][Full Text] [Related]